Most cited papers from Humanigen (United States)

Humanigen (United States)

What are the most cited papers from Humanigen (United States)?

The most cited paper from Humanigen (United States) is "GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts" (Rosalie M. Sterner et al., 2018), with 640 citations. Next come "α-Skeletal and α-Cardiac Actin Genes Are Coexpressed in Adult Human Skeletal Muscle and Heart" (234) and "GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia" (89).

Published TypeFieldAccessAuthors

Showing 32 of 32 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts Rosalie M. Sterner et al. · Blood Open access	22 Nov 2018	640
2	α-Skeletal and α-Cardiac Actin Genes Are Coexpressed in Adult Human Skeletal Muscle and Heart Peter William Gunning, Phyllis A. Ponte, Helen M. Blau et al. · Molecular and Cellular Biology Open access	Nov 1983	234
3	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia Zelalem Temesgen et al. · Mayo Clinic Proceedings Open access	3 Sep 2020	89
4	Cardiac Actin Is the Major Actin Gene Product in Skeletal Muscle Cell Differentiation In Vitro William Bains, Phyllis A. Ponte, Helen M. Blau et al. · Molecular and Cellular Biology	Aug 1984	74
5	Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial Zelalem Temesgen et al. · The Lancet Respiratory Medicine Open access124 authors	Dec 2021	74
6	Two-Level Regulation of Cardiac Actin Gene Transcription: Muscle-Specific Modulating Factors Can Accumulate before Gene Activation Adrian J. Minty, Helen M. Blau, Larry Kedes · Molecular and Cellular Biology	Jun 1986	55
7	Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia Mrinal M. Patnaik, David Andrew Sallman, Abhishek Avinash Mangaonkar et al. · Blood Open access	15 Apr 2020	54
8	GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity Michelle J. Cox et al. · Leukemia Open access	19 Apr 2022	42
9	Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19 Joshua C. Pritchett, Bijan J. Borah, Aakash P. Desai et al. · JCO Oncology Practice Open access	4 Jun 2021	35
10	LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL Zelalem Temesgen, Charles D. Burger, Jason V. Baker et al. · medRxiv PreprintOpen access	5 May 2021	34
11	Avian Embryonic Stem Cells Marie‐Cecile van de Lavoir, Christine Mather-Love · Methods in enzymology on CD-ROM/Methods in enzymology Book chapter	2006	29
12	First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia Zelalem Temesgen, Mariam Assi, Paschalis I. Vergidis et al. · medRxiv PreprintOpen access	12 Jun 2020	27
13	Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF Miriam Sayuri Hohmann et al. · JCI Insight Open access	4 May 2021	25
14	CAR-T–cell neurotoxicity: hope is on the horizon Omar Abdihamid · Blood Open access	16 May 2019	16
15	ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma Olalekan O. Oluwole, Saad S. Kenderian, Parveen Shiraz et al. · Blood	15 Nov 2022	15
16	ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL) Saad S. Kenderian, Olalekan O. Oluwole, Philip L. McCarthy et al. · Blood	4 Nov 2020	12
17	C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial Zelalem Temesgen, Colleen Frances Kelley, Frank Cerasoli et al. · Thorax Open access	6 Jul 2022	11
18	Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective Adrian Kilcoyne, E. O. Jordan, Allen S. Zhou et al. · Journal of Medical Economics Open access	17 Jan 2022	7
19	GM-CSF Blockade during Chimeric Antigen Receptor T-Cell (CART) Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance CART Effector Functions Rosalie M. Sterner et al. · Transplantation and Cellular Therapy Open access	31 Jan 2019	6
20	Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England Adrian Kilcoyne, Edward Jordan, Kimberly Thomas et al. · ClinicoEconomics and Outcomes Research Open access	Apr 2022	5
21	Phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma Hui Kong Gan et al. · Journal of Nuclear Medicine	May 2020	5
22	EARLY LENZILUMAB TREATMENT OF COVID-19 PATIENTS USING C-REACTIVE PROTEIN AS A BIOMARKER IMPROVES EFFICACY: RESULTS FROM THE PHASE 3 ‘LIVE-AIR’ TRIAL Zelalem Temesgen, Colleen Frances Kelley, Franklin Cerasoli et al. · medRxiv PreprintOpen access	2022	4
23	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts Michelle J. Cox, Charles J. Kuhlmann, Rosalie M. Sterner et al. · Transplantation and Cellular Therapy Open access	23 Jan 2020	3
24	COVID-19 associated chronic ARDS successfully treated with lenzilumab Juan D Pulido, Omar Ahmed, Rida Rasool et al. Preprint	Oct 2020	2
25	P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL David M. Ross, Devendra Hiwase, Steven Lane et al. · HemaSphere Open access	Aug 2023	0
26	1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation Dale Chappell, Adrian Kilcoyne, Frank Cerasoli et al. · Open Forum Infectious Diseases Open access	Dec 2022	0
27	LENZILUMAB OUTCOMES ACCORDING TO RACE OF COVID-19 PARTICIPANTS IN THE LIVE-AIR PHASE 3 TRIAL Vincent C. Marconi, Adrian Kilcoyne, Franklin Cerasoli et al. · medRxiv PreprintOpen access	21 Aug 2022	0
28	ICLAS LAQ Network for the Promotion of Animal Quality in Research Patri Vergara, Gregory Ballard, Cynthia L Besch-Williford et al. · ILAR Journal Open access	2021	0
29	23: LENZILUMAB IN HOSPITALIZED BLACK/AFRICAN-AMERICAN COVID-19 PATIENTS: LIVE-AIR PHASE 3 STUDY RESULTS Zelalem Temesgen, Charles D. Burger, Claudia R. Libertin et al. · Critical Care Medicine	16 Dec 2021	0
30	S51 Evaluation of treatment approaches for hospitalized Covid-19 patients Adrian Kilcoyne, E. O. Jordan, Cameron Durrant et al. Conference paperOpen access	Nov 2021	0
31	Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective Adrian Kilcoyne, E. O. Jordan, Allen S. Zhou et al. · medRxiv PreprintOpen access	10 Oct 2021	0
32	GM-CSF disruption in cart cells ameliorates cart cell activation and reduces activation-induced cell death Michelle J. Cox, Claudia Manriquez Roman, Reona Leo Sakemura et al. · Cytotherapy	May 2021	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.